BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 33509276)

  • 41. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.
    Kühnl A; Valk PJ; Sanders MA; Ivey A; Hills RK; Mills KI; Gale RE; Kaiser MF; Dillon R; Joannides M; Gilkes A; Haferlach T; Schnittger S; Duprez E; Linch DC; Delwel R; Löwenberg B; Baldus CD; Solomon E; Burnett AK; Grimwade D
    Blood; 2015 May; 125(19):2985-94. PubMed ID: 25805812
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.
    Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J
    Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases.
    Hong S; Cho YW; Yu LR; Yu H; Veenstra TD; Ge K
    Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18439-44. PubMed ID: 18003914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia.
    Saeed S; Logie C; Francoijs KJ; Frigè G; Romanenghi M; Nielsen FG; Raats L; Shahhoseini M; Huynen M; Altucci L; Minucci S; Martens JH; Stunnenberg HG
    Blood; 2012 Oct; 120(15):3058-68. PubMed ID: 22923494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytometry.
    Watson M; Chow S; Barsyte D; Arrowsmith C; Shankey TV; Minden M; Hedley D
    Cytometry A; 2014 Jan; 85(1):78-87. PubMed ID: 24038859
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells.
    Spencer DH; Young MA; Lamprecht TL; Helton NM; Fulton R; O'Laughlin M; Fronick C; Magrini V; Demeter RT; Miller CA; Klco JM; Wilson RK; Ley TJ
    Leukemia; 2015 Jun; 29(6):1279-89. PubMed ID: 25600023
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The epigenome of AML stem and progenitor cells.
    Yamazaki J; Estecio MR; Lu Y; Long H; Malouf GG; Graber D; Huo Y; Ramagli L; Liang S; Kornblau SM; Jelinek J; Issa JP
    Epigenetics; 2013 Jan; 8(1):92-104. PubMed ID: 23249680
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
    Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
    Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.
    Haferlach C; Mecucci C; Schnittger S; Kohlmann A; Mancini M; Cuneo A; Testoni N; Rege-Cambrin G; Santucci A; Vignetti M; Fazi P; Martelli MP; Haferlach T; Falini B
    Blood; 2009 Oct; 114(14):3024-32. PubMed ID: 19429869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of Retinal Development via the Epigenetic Modification of Histone H3.
    Watanabe S; Murakami A
    Adv Exp Med Biol; 2016; 854():635-41. PubMed ID: 26427469
    [TBL] [Abstract][Full Text] [Related]  

  • 51. OTX2 sustains a bivalent-like state of OTX2-bound promoters in medulloblastoma by maintaining their H3K27me3 levels.
    Bunt J; Hasselt NA; Zwijnenburg DA; Koster J; Versteeg R; Kool M
    Acta Neuropathol; 2013 Mar; 125(3):385-94. PubMed ID: 23179372
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.
    Tao YF; Xu LX; Lu J; Hu SY; Fang F; Cao L; Xiao PF; Du XJ; Sun LC; Li ZH; Wang NN; Su GH; Li YH; Li G; Zhao H; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Zhu XM; Ni J; Wang J; Xing F; Zhao WL; Pan J
    J Exp Clin Cancer Res; 2015 Jan; 34(1):4. PubMed ID: 25609158
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
    Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
    Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
    Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
    J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Down-regulation of JARID1B expression inhibits cell proliferation, induces apoptosis and blocks cell cycle in human acute lymphoblastic leukemia cells.
    Huang YQ; Zou Y; Zheng RJ; Ma XD
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1366-1373. PubMed ID: 29565495
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.
    Assaf N; El-Cheikh J; Bazarbachi A; Salem Z; Farra C; Chakhachiro Z; Nassif S; Zaatari G; Mahfouz R
    Mol Biol Rep; 2019 Apr; 46(2):2003-2011. PubMed ID: 30701458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia.
    Lian XY; Ma JC; Zhou JD; Zhang TJ; Wu DH; Deng ZQ; Zhang ZH; Li XX; He PF; Yan Y; Lin J; Qian J
    J Cell Physiol; 2019 Jun; 234(6):9438-9446. PubMed ID: 30317626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of epigenetic modifications that contribute to pathogenesis in therapy-related AML: Effective integration of genome-wide histone modification with transcriptional profiles.
    Yang XH; Wang B; Cunningham JM
    BMC Med Genomics; 2015; 8 Suppl 2(Suppl 2):S6. PubMed ID: 26043758
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
    Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
    Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.